Literature DB >> 25336498

Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.

Luigi Marzano1, Gianluca Colussi2, Leonardo A Sechi2, Cristiana Catena2.   

Abstract

BACKGROUND: Primary aldosteronism (PA) is associated with an increase in left ventricular (LV) mass beyond the amount needed to compensate the hypertension-related workload. Available evidence suggests effectiveness of surgical treatment of PA in decreasing LV mass, whereas data on medical treatment are controversial. We have conducted a meta-analysis of long-term follow-up studies on surgical and medical treatment of PA to compare the effects of treatments on LV mass.
METHODS: Medline and Cochrane searches were performed including the following words: hyperaldosteronism, left ventricular mass, mineralocorticoid receptor antagonists, surgery, adrenalectomy, and follow-up studies. Studies published within 2013 focusing on cardiac effects of treatment and follow-up longer than 6 months were selected. Data extraction was performed independently by 2 authors.
RESULTS: Of 61 retrieved articles, 4 were included in the analysis. These studies enrolled 355 patients with PA who had an average follow-up of 4.0 years after unilateral adrenalectomy (n = 178) or treatment with mineralocorticoid receptor antagonists (n = 177). Despite greater effect of surgery over medical treatment in reducing blood pressure, meta-analysis of the selected studies demonstrated no significant difference in LV mass change between patients with PA who were treated with mineralocorticoid receptor antagonists or adrenalectomy (standard mean difference = 0.130; 95% confidence interval = -0.085 to 0.345; P = 0.24; I2 = 0%).
CONCLUSIONS: Available evidence indicates that reduction of LV mass is not different in PA patients treated with adrenalectomy or mineralocorticoid receptor antagonists. © American Journal of Hypertension, Ltd 2014. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  adrenalectomy; blood pressure; hyperaldosteronism; hypertension; left ventricular hypertrophy; left ventricular mass; mineralocorticoid receptor antagonists.

Mesh:

Substances:

Year:  2014        PMID: 25336498     DOI: 10.1093/ajh/hpu154

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  12 in total

Review 1.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

2.  MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction.

Authors:  Maryam Syed; Jana P Ball; Keisa W Mathis; Michael E Hall; Michael J Ryan; Marc E Rothenberg; Licy L Yanes Cardozo; Damian G Romero
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

Review 3.  Approach to the surgical management of primary aldosteronism.

Authors:  Maurizio Iacobone; Marilisa Citton; Giovanni Viel; Gian Paolo Rossi; Donato Nitti
Journal:  Gland Surg       Date:  2015-02

Review 4.  Treatment of Primary Aldosteronism and Organ Protection.

Authors:  Cristiana Catena; GianLuca Colussi; Leonardo A Sechi
Journal:  Int J Endocrinol       Date:  2015-05-17       Impact factor: 3.257

5.  Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism.

Authors:  Marianne Aa Grytaas; Kjersti Sellevåg; Hrafnkell B Thordarson; Eystein S Husebye; Kristian Løvås; Terje H Larsen
Journal:  Endocr Connect       Date:  2018-02-12       Impact factor: 3.335

Review 6.  Progress in the Management of Primary Aldosteronism.

Authors:  Ryo Morimoto; Kei Omata; Sadayoshi Ito; Fumitoshi Satoh
Journal:  Am J Hypertens       Date:  2018-04-13       Impact factor: 2.689

7.  Endogenous Purification of NR4A2 (Nurr1) Identified Poly(ADP-Ribose) Polymerase 1 as a Prime Coregulator in Human Adrenocortical H295R Cells.

Authors:  Erika Noro; Atsushi Yokoyama; Makoto Kobayashi; Hiroki Shimada; Susumu Suzuki; Mari Hosokawa; Tomohiro Takehara; Rehana Parvin; Hiroki Shima; Kazuhiko Igarashi; Akira Sugawara
Journal:  Int J Mol Sci       Date:  2018-05-08       Impact factor: 5.923

8.  Predicting factors related with uncured hypertension after retroperitoneal laparoscopic adrenalectomy for unilateral primary aldosteronism.

Authors:  WuYun BiLiGe; Chaoqi Wang; JiRiGaLa Bao; Dahai Yu; A Min; Zhi Hong; Xiangbao Chen; Min Wang; Dongmei Wang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

9.  A Prospective Comparative Study on Cardiac Alterations After Surgery and Drug Treatment of Primary Aldosteronism.

Authors:  Yi-Lin Chen; Ting-Yan Xu; Jian-Zhong Xu; Li-Min Zhu; Yan Li; Ji-Guang Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-11       Impact factor: 5.555

Review 10.  Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy.

Authors:  Chiara Sabbadin; Alessandra Andrisani; Guido Ambrosini; Luciana Bordin; Gabriella Donà; Jacopo Manso; Filippo Ceccato; Carla Scaroni; Decio Armanini
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-23       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.